Prostate Cancer Coverage from Every Angle
Editor:
Sandy Srinivas, MD
Advertisement
Advertisement

Videos

Sandy Srinivas, MD, on Treatment Alternatives for Metastatic Castration-Resistant Prostate Cancer During Radioligand Therapy Shortage

Alex K. Bryant, MD, on Association Between PSA Screening Rates and Prostate Cancer Incidence in U.S. Veterans

Rahul Aggarwal, MD, on Clinical Implications of the PRESTO Study Findings in Prostate Cancer

Alicia K. Morgans, MD, MPH, on Metastatic and Nonmetastatic Prostate Cancer: New Findings on Androgen-Deprivation Therapy

Scott T. Tagawa, MD, on Clinical Implications of Using an Anti-PSMA Antibody With Ketoconazole, Hydrocortisone, and Lutetium-177 in Treatment of Prostate Cancer

Neal D. Shore, MD, on New Data on the Safety and Efficacy of Darolutamide in Patients With Prostate Cancer

Alan H. Bryce, MD, on Clinical Implications of Findings on Rucaparib, Docetaxel, and Androgen Pathway Inhibitor Therapy for Prostate Cancer

Paul L. Nguyen, MD, on Salvage Radiotherapy, GnRH Agonist, Abiraterone, Prednisone, and Apalutamide in Prostate Cancer Treatment

Tanya Dorff, MD, on Androgen Deprivation, External-Beam Radiation Therapy, and Oligometastatic Hormone-Sensitive Prostate Cancer

Tanya Dorff, MD, on New Findings on Talazoparib Monotherapy in Prostate Cancer

Anthony V. D’Amico, MD, PhD, on Adjuvant vs Early Salvage Radiation Therapy After Prostatectomy

Neeraj Agarwal, MD, on Pairing Androgen-Deprivation Therapy With a CYP17 Inhibitor to Treat Metastatic Prostate Cancer

Peter C. Black, MD, on Improving Prostate Cancer Outcomes for Black Men

Michael J. Morris, MD: Can Lutetium-177–PSMA-617 Plus Standard of Care Improve Outcomes in Advanced Prostate Cancer?

Karim Fizazi, MD, PhD, on Whether or How to Combine Prostate Cancer Treatments

Sandy Srinivas, MD, on Balancing Quality of Life and Survival When Making Decisions About Prostate Cancer Treatment

Neeraj Agarwal, MD, on Clinical Implications of TITAN Trial Findings on Apalutamide Plus Androgen-Deprivation Therapy for Advanced Prostate Cancer

Felix Y. Feng, MD, on Predicting the Efficacy of Apalutamide in Patients With Castration-Resistant Prostate Cancer

Christopher Sweeney, MBBS, on Treating Prostate Cancer With PI3K/AKT Pathway Alterations

Nicholas D. James, PhD, MBBS, on Clinical Implications of STAMPEDE Trial Results: Abiraterone Acetate Plus Prednisolone in Prostate Cancer

Daniel P. Petrylak, MD, on Understanding ARV-110, an Oral PROTAC Degrader for Prostate Cancer Treatment

Michael J. Morris, MD, on PSMA-Targeted Imaging for Prostate Cancer: CONDOR Trial

Neal D. Shore, MD, on a Possible New Standard of Care in Oral Therapy for Advanced Prostate Cancer

Rana R. McKay, MD: Which Patients Might Benefit From Neoadjuvant Androgen Deprivation Before Radical Prostatectomy?

Amir Goldkorn, MD, on Challenges of Integrating a Prostate Cancer Prognostic Marker Into Standard Practice

Michael S. Hofman, MBBS, on LuPSMA vs Cabazitaxel: Clinical Implications of the ANZUP 1603 Prostate Cancer Trial

Christopher Sweeney, MBBS, on Prostate Cancer: IMbassador250 Trial on Atezolizumab and Enzalutamide

Julie N. Graff, MD, on Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant Metastatic Castration-Resistant Disease

Hannah L. Rush, MBChB, on Self-Reported Quality of Life in the STAMPEDE Trial

Karim Fizazi, MD, PhD, on Chemotherapy vs Endocrine Therapy: Patient-Reported Outcomes

David P. Dearnaley, MD, on Helping Patients Tolerate Radiation Therapies for Prostate Cancer

Maha H.A. Hussain, MD, on Managing Nausea and Fatigue in Men Treated for Prostate Cancer

Nicholas D. James, PhD, MBBS, on Frequency of Imaging Studies in Patients Treated With Enzalutamide

Maha H.A. Hussain, MD, on Castration-Resistant Prostate Cancer: Future Directions for PARP Inhibitors

Ryan Phillips, MD, PhD, on Observation or Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer?

Daniel E. Spratt, MD, on Pros and Cons of Antiandrogen Treatment in Prostate Cancer

Michael J. Morris, MD, on the Alliance Trial: Clinical Implications of Combination Therapy for Prostate Cancer

Kim N. Chi, MD, on Adding Apalutamide to Androgen-Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer

Karim Fizazi, MD, PhD, on Darolutamide Treatment in Prostate Cancer: Helping Patients Assess Benefits vs Risks

Christopher Sweeney, MBBS, on Adding Enzalutamide to the Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer

James L. Mohler, MD, on Prostate Cancer: An Update on Treatment Recommendations

Sumit K. Subudhi, MD, PhD, on Managing Apalutamide Toxicities in Prostate Cancer

Howard I. Scher, MD, on Managing Enzalutamide Toxicities in Prostate Cancer

Sumit K. Subudhi, MD, PhD, on Monitoring the Progress of Prostate Cancer Treated With Apalutamide

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Nicholas D. James, PhD, MBBS, on Radiotherapy and Abiraterone in Prostate Cancer

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Carmel Jo Pezaro, MB, ChB, on Prostate Cancer and PARP Inhibitors

James L. Mohler, MD, on Prostate Cancer: Updated NCCN Recommendations

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Peter R. Carroll, MD, MPH, on Prostate Cancer: Risks of Early Detection

Maha Hussain, MD, and Eric J. Small, MD, on Prostate Cancer and Antiandrogens: Results From the PROSPER and SPARTAN Trials

The JNCCN Spotlight

Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.